New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.
about
Genetic and structural validation of Aspergillus fumigatus N -acetylphosphoglucosamine mutase as an antifungal targetCandida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005Identification of antifungal compounds active against Candida albicans using an improved high-throughput Caenorhabditis elegans assayAntifungal efficacy during Candida krusei infection in non-conventional models correlates with the yeast in vitro susceptibility profileManagement and Novel Adjuncts of Necrotizing Soft Tissue Infections.A role for the unfolded protein response (UPR) in virulence and antifungal susceptibility in Aspergillus fumigatus.Caenorhabditis elegans-based model systems for antifungal drug discovery.Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a case report and review of the literature.Characterization of plant-derived saponin natural products against Candida albicans.Synthesis and antifungal activity of functionalized 2,3-spirostane isomersAntifungal activity of redox-active benzaldehydes that target cellular antioxidation.Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testGeographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.Cryptococcus neoformans phosphoinositide-dependent kinase 1 (PDK1) ortholog is required for stress tolerance and survival in murine phagocytesTriazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazoleMultilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei.Antimicrobial treatment for intra-abdominal infections.Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testingInvasive pulmonary aspergillosis in patients with COPD: a report of five cases and systematic review of the literature.Epidemiology and management of cryptococcal meningitis: developments and challenges.Fusarium infection in lung transplant patients: report of 6 cases and review of the literature.Itraconazole induces apoptosis and cell cycle arrest via inhibiting Hedgehog signaling in gastric cancer cells.The strategy of antibiotic use in critically ill neutropenic patientsCandida peritonitis: an update on the latest research and treatments.Discovery and characterization of ß-1,6-glucan inhibitors.In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.Fungicide Xylaria sp. BCC 1067 extract induces reactive oxygen species and activates multidrug resistance system in Saccharomyces cerevisiae.Enhanced activity of antifungal drugs using natural phenolics against yeast strains of Candida and Cryptococcus.Persistent spontaneous fungal peritonitis secondary to Candida albicans in a patient with alcoholic cirrhosis and review of the literature.Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections.Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008).Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by useIn vivo and in vitro acquisition of resistance to voriconazole by Candida krusei.Successful treatment of invasive gastric mucormycosis in a patient with alcoholic liver cirrhosis: A case report.A high-throughput assay of yeast cell lysis for drug discovery and genetic analysis.Post-traumatic osteomyelitis due to Aspergillus flavus successfully treated with voriconazole: a case report.Aggressive cutaneous squamous cell carcinoma associated with prolonged voriconazole therapy in a renal transplant patient.
P2860
Q27679053-25CD6EE9-2831-4272-A0E6-507459348A5BQ28260910-D7C7D0DD-CACB-424E-A84A-DBF0AF9A41E5Q28476138-7FF2E37E-9B9A-44F3-A82E-9CDC54440D24Q28489096-1453DCDF-A1D7-4814-8DED-280C9C7D4C21Q30234954-FFFFE86F-F4D6-405C-9839-8C430BA71CFEQ33398514-2F70C419-D388-463D-8B57-9F940A5BB6B5Q33864072-3DDCB276-1758-4315-8A3C-9CA09FCBE323Q33911297-7FE6114D-087B-4476-AB73-FE44EBA5BF0BQ34248026-DA31428B-4CC8-49C0-9EDB-0C5B38FC5BEFQ34953266-939699C3-A155-43DF-B845-45DD3F7CAD77Q35081105-0DF2601A-69A0-4651-B3DA-550114605419Q35913918-30A891A3-836D-4766-B339-8EEDAAC4FC7DQ36497888-6175A5D6-02BE-45A5-A389-067D855765C9Q36505126-D9C65055-C0B7-46CF-B108-D1FD7CC3BE04Q36521993-9D5BC3BB-BC06-4077-91B6-7F4FA9FD0A0DQ36538716-575B930F-39C8-4CB4-99BB-53A3A507A539Q37000729-350A45B1-43D5-4C2E-9222-F67492BD71F0Q37051529-0CEC9020-1FBD-4C5F-AF5A-67DC6D910E60Q37095685-AB6ECD7F-54D1-47C1-AFFD-7A573B5C71A7Q37098995-204A22AA-CC65-4414-97BD-0B9AA1E4F655Q37114436-2B2324D3-75D2-42DA-9834-0B4592157269Q37747533-2AE251CA-C444-4986-BD21-B63C17C86B20Q37929895-4F37392E-8FA5-48D3-BADB-E47FAA6A3AA8Q37942794-83ED3D55-E350-4642-BF05-481CC1F9FD86Q38029139-CFA021F5-6D11-4EEC-A8E9-C3560C89A25CQ38725931-111CEA8C-209F-48A3-AD6D-4F5D6167E47DQ38737357-5C24337D-8FB4-4FF4-BB78-E60CA6566EC4Q38999537-ED0EE1E7-0631-413C-A2B1-D767C82270F6Q39016489-6EFC8F77-CC6B-4595-A2F1-AD2786226B06Q39215244-74220B31-5D5C-4248-986E-D755E1CBB111Q39899742-7416659F-D662-4401-A869-7E41460046A3Q41833155-FD4616B0-9991-4EEF-B3A3-1EB98962641FQ41893115-61D0AC12-C0EF-4FA9-846E-8F92B01B8457Q41908299-D4135119-F320-4DF3-8A64-AF917BBA5858Q41969487-FD6DADA7-3D65-413E-AECE-3E3E208BCF35Q42109755-4C88BEB6-04A8-4F28-9CD9-21DBFD7675EFQ42718261-7DDBA52A-DDFC-4BFF-B56D-3B8122C751CBQ43030507-72F299F1-7BF1-450E-8D2F-8F16D946F4C8Q44766135-77003A08-ABEB-4A60-9AEB-60887A37FB40Q46763769-C87646B1-A035-4EF3-8E4A-14249A2545BE
P2860
New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
New agents for the treatment o ...... efficacy and gaps in coverage.
@ast
New agents for the treatment o ...... efficacy and gaps in coverage.
@en
type
label
New agents for the treatment o ...... efficacy and gaps in coverage.
@ast
New agents for the treatment o ...... efficacy and gaps in coverage.
@en
prefLabel
New agents for the treatment o ...... efficacy and gaps in coverage.
@ast
New agents for the treatment o ...... efficacy and gaps in coverage.
@en
P2860
P356
P1476
New agents for the treatment o ...... efficacy and gaps in coverage.
@en
P2093
Elias K Spanakis
George Aperis
P2860
P304
P356
10.1086/507891
P407
P577
2006-09-08T00:00:00Z